SANIONA AB [CBOE] news, videos and press releases - Page 3
For more news please use our advanced search feature.
SANIONA AB [CBOE] - More news...
SANIONA AB [CBOE] - More news...
- Saniona publishes its year-end report for 2020
- Saniona Announces Oral Presentation of Tesomet Data in Hypothalamic Obesity at ENDO 2021
- Saniona to Present at the Oppenheimer 31st Annual Healthcare Conference
- Saniona Receives Feedback from U.S. FDA Providing a Regulatory Path Forward for Tesomet in Hypothalamic Obesity
- Saniona Receives U.S. FDA Orphan Drug Designation for Tesomet in Prader-Willi Syndrome
- Saniona postpones 2020 year-end financial report due to restatement and re-audit of prior period financial statements in line with U.S. PCAOB audit standards
- Saniona received approximately USD $2.9 million (SEK 24.2 million) upfront payment in connection with Cadent Therapeutics transaction
- Saniona to present at three upcoming investor conferences
- Saniona Appoints Chief Legal Officer and Chief Technical Operations Officer to Its Executive Team
- Saniona was informed today that Novartis plans to acquire Cadent Therapeutics, in which Saniona holds an ownership stake of approximately 3%
- Saniona’s Ownership Stake in Scandion Oncology Reduced Below 5% Following Scandion’s Successful Rights Issue
- Saniona publishes its interim report for the third quarter 2020
- Saniona AB’s Nomination Committee for the Annual General Meeting 2021
- Saniona Reports Positive Topline Results from Tesomet Phase 2 Open-Label Extension Study in Hypothalamic Obesity
- Saniona to Participate in Stifel and Jefferies Virtual Investor Conferences in November
- Saniona Refines Pipeline to Focus on Rare Diseases; Regains GABAa5 Negative Allosteric Modulator Program from Boehringer Ingelheim
- Saniona Changes Date of Interim Report for Q3 2020
- Bulletin from the extraordinary general meeting on October 23, 2020 in Saniona AB
- Saniona receives pre-IND feedback from FDA on regulatory path for Tesomet in Prader-Willi Syndrome (PWS) and Hypothalamic Obesity (HO)
- Change in numbers of shares and votes in Saniona AB (publ)
- Notice of extraordinary general meeting in Saniona AB
- Saniona announces outcome of warrant exercise
- Saniona to Participate in Oppenheimer’s Virtual 2020 Fall Healthcare Life Sciences & MedTech Summit
- Saniona announces that the exercise period of warrants of series TO 2 begins on September 7, 2020
- Change in numbers of shares and votes in Saniona AB (publ)
- Saniona publishes its interim report for the second quarter 2020
- Saniona Expands Executive Team with Appointments of Chief Financial Officer, Chief Communications Officer and Chief Human Resources Officer
- Saniona Announces Poster Presentation at the European Congress of Endocrinology Virtual Annual Meeting
- Saniona invites investors to participate in a conference call and webcast presentation regarding its recent $65 million financing
- Saniona publishes prospectus regarding admission to trading of newly issued shares on Nasdaq Stockholm